GSK plc (GSK,GSK.L) said that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration or NMPA has accepted for review the regulatory application of Shingrix (Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster) in adults aged 18 years and over at increased risk.Recombinant Zoster Vaccine (RZV) is a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses and was initially approved in 2019 by the NMPA to prevent shingles in adults aged 50 years and over.Shingles is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox.

葛兰素史克股份有限公司（GSK，GSK.L）表示，中国国家医药管理局（NMPA）药物评估中心（CDE）已接受审查Shingrix（重组带状疱疹疫苗或RZV）在18岁及以上风险增加的成年人中预防带状疱疹（herpes Zoster）的监管应用。重组带状疱疹疫苗（RZV）是一种非活的重组亚单位佐剂疫苗，分两次肌肉注射，最初于2019年获得NMPA批准，用于预防50岁及以上成年人的带状疱疹。带状疱疹是由水痘带状疱疹病毒（VZV）的再激活引起的，该病毒与引起水痘的病毒相同。

A variety of factors can increase the risk of developing shingles, including advancing age and immunodeficiency or immunosuppression, as well as other chronic conditions such as COPD, diabetes, and asthma..

多种因素会增加患带状疱疹的风险，包括年龄增长、免疫缺陷或免疫抑制，以及其他慢性病，如COPD、糖尿病和哮喘。。

For More Such Health News, visit rttnews.com For comments and feedback contact: editorial@rttnews.comBusiness News

有关更多此类健康新闻，请访问rttnews.com获取评论和反馈联系方式：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In October 2023

2023年10月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in August 2023

2023年8月美国食品和药物管理局（FDA）决定生物技术股